Navigation Links
SK Life Sciences has Licensed Pristima
Date:8/5/2009

Xybion Medical Systems, is pleased to announce that SK Life Science, Inc. (SKLSI), has licensed Pristima for its Research and Development facility in Fair Lawn, New Jersey.

Cedar Knolls, NJ (PRWEB) August 3, 2009 -- Xybion Medical Systems, a world leader in toxicology and pathology data management solutions and the developer of Pristima™ the premier preclinical solution on the market, is pleased to announce that SK Life Science, Inc. (SKLSI), has licensed Pristima for its Research and Development facility in Fair Lawn, New Jersey.

After extensive research and evaluation of the products on the market, SKLSI selected Xybion's Pristima to manage its general toxicology data as well as licensing Xybion's Standard Validation Package and contracting Xybion to perform the full suite of installation, training and validation execution services. Additionally, SKLSI has contracted to have Xybion's professional services team perform all of the hardware installation, third-party software installation and all other IT services related to Pristima.

Dr. Pradip Banerjee, Xybion's CEO, stated that "we are proud to add SK Life Science, Inc., another leading global research and development company to our growing community. We are tremendously satisfied that SKLSI has acknowledged Pristima to be the most powerful system on the market. Pristima is designed to account for all types of toxicology studies and is specifically well-suited to collect, manage and summarize data for global pharmaceutical and chemical companies as well as contract research organizations."

Dr. Hong Wook Kim, Director, Non-clinical Development of SK Life Science, Inc., remarked that "SKLSI is building its research and development arm and required the most modern toolset in order to address current and future projects."

About SK Life Sciences - SK Life Science, Inc. (

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Human Genome Sciences Announces Closing of Public Offering
2. Advanced Life Sciences Receives Complete Response Letter From FDA for Restanza(TM) (Cethromycin) in Community Acquired Pneumonia
3. Caliper Life Sciences Reports Second Quarter 2009 Results
4. Sangamo BioSciences Reports Second Quarter 2009 Financial Results
5. Neurocrine Biosciences Reports Second Quarter 2009 Results
6. ImmuneRegen BioSciences Confirms Homsperas Therapeutic Anti-Influenza Effect on Pandemic H1N1 Influenza Virus After Oral Administration
7. Marinus Pharmaceuticals Adds Two Life Sciences Veterans to its Board of Directors
8. SAFC Biosciences(R) Defines Hydrolysate Components That Enhance Chinese Hamster Ovary (CHO) Cell Line Protein Production
9. Human Genome Sciences Announces Pricing of Public Offering of Common Stock
10. Human Genome Sciences Announces Proposed Public Offering of Common Stock
11. Webcast Alert: Neurocrine Biosciences Announces 2nd Quarter 2009 Earnings Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Texas , Dec. 16, 2014  Vermillion, Inc. ... focused on gynecologic disease, today announced the next step ... a premier bio-analytics solutions provider with the naming of ... President and Chief Executive Officer, while current Chairman of ... continue to serve as Chairman. These changes are effective ...
(Date:12/17/2014)... 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... development and commercialization of innovative therapeutics addressing cancer and ... a primary commercial focus on China ... Type C meeting with the U.S. Food and Drug ... in February 2015.  During this meeting the Company will ...
(Date:12/17/2014)...   Synageva BioPharma Corp. (NASDAQ: ... rare disorders, announced today its presentation at the upcoming ... San Francisco, CA. Sanj ... present on Monday, January 12, 2015, at 9:00 a.m. ... live and may be accessed from the "Webcasts & ...
(Date:12/15/2014)... PETACH TIKVAH, Israel , Dec. 15, ... BCLI ), a leading developer of adult stem cell ... Brainstorm Cell Therapeutics Ltd. was awarded a grant of ... Office of the Chief Scientist (OCS).  This is the ... grant support from the Office of the Chief Scientist, ...
Breaking Biology Technology:Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3
... , SHANGHAI, Nov. ... Drug Administration (SFDA) has approved the,investigational new drug application (IND) ... treat diabetes. This IND,approval allows Biolaxy to initiate its first ... is a disorder characteristic of high blood glucose and poor,metabolism. ...
... ... by laboratories participating in or generating DNA records for the National DNA Index System. ... Madison, WI USA (PRWEB) -- ... laboratories participating in, or generating DNA records for, the National DNA Index System (NDIS). NDIS ...
... HTL , TORONTO, Nov. 24 /PRNewswire-FirstCall/ - Hamilton Thorne Ltd. (TSX-V: ... systems and instruments for the stem cell research and fertility clinic ... ended September 30, 2009. , , Q3 2009 ... compared with $1.43 million in Q3 2008, - ...
Cached Biology Technology:Biolaxy Secures IND Approval for Oral Insulin 2NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7Hamilton Thorne announces third quarter results 8Hamilton Thorne announces third quarter results 9Hamilton Thorne announces third quarter results 10
(Date:12/10/2014)... , December 9, 2014 ... BCARD Platform   ... meeting scheduling solutions for business-to-business (B2B) events, today ... leader in mobile near-field communication (NFC), Bluetooth low ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will ...
(Date:12/5/2014)... -- Tute Genomics, a leader in cloud-based solutions for genome ... led by UK-based Eurovestech. Peak Ventures and a number ... "We are at a pivotal time in ... seeks new approaches for the diagnosis, treatment and prevention ... and CEO of Tute Genomics. "One of the main ...
(Date:12/3/2014)...   Marvin Test Solutions , a trusted ... military, aerospace, and manufacturing organizations, today announced the ... TS-900 PXI semiconductor test platform . The TS-960 ... to customers at a fraction of the footprint ... "Our semiconductor customers asked for ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... the Electronic Nose, which has the potential to diagnose ... grant from Grand Challenges Canada and the Bill & ... testing of this ground-breaking technology. The ... able to detect TB immediately and non-invasively from the ...
... family of compounds that includes one of the most ... treatments. But the difficulty producing these complex molecules in ... family for further drug leads. Now, a group of ... step toward the goal of synthetically producing Taxol and ...
... name "Sleeping Beauty" has helped to unlock vital clues ... A study published today used the Sleeping Beauty transposon ... drive colorectal cancer, identifying many more than previously thought. ... human cancer, which provides strong evidence that they are ...
Cached Biology News:Creating an 'electronic nose' to sniff out tuberculosis from a patient's breath 2Scripps research team achieves critical step to opening elusive class of compounds to drug discovery 2Scripps research team achieves critical step to opening elusive class of compounds to drug discovery 3Scripps research team achieves critical step to opening elusive class of compounds to drug discovery 4Researchers discover genes involved in colorectal cancer 2